Talkspace remains a compelling small-cap value play amid tech sector volatility and macro uncertainty. TALK's Q4 earnings beat fueled a 25% rally, with shares up over 50% in the past year and strong momentum expected to continue. Guidance for FY26 calls for $275–290M revenue (20–27% growth) and $30–35M adjusted EBITDA, with margin expansion driven by payor and enterprise focus.

The need for high-quality therapy is rising. Talkspace is becoming more profitable as it scales its operations.

Talkspace, Inc. (TALK) Q4 2025 Earnings Call Transcript

Talkspace, Inc. (TALK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.01 per share a year ago.

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Talkspace, Inc. (“Talkspace” or the “Company”) (NASDAQ: TALK), today reported fourth quarter and full year 2025 financial results.

Talkspace (NASDAQ: TALK - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Profitability This table compares Talkspace and Pulmonx's net margins,

Talkspace (NASDAQ: TALK - Get Free Report) is projected to release its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $61.9110 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning overview page

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK),  a leading behavioral healthcare company, today announced that it will release its fourth quarter and full year 2025 results on Thursday, February 19, 2026 before market open and host a conference call to review the results at 8:30am ET.

Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Talkspace (NASDAQ: TALK - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Valuation and Earnings This table compares Evaxion A/S

Talkspace, Inc. (TALK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript